The World Health Organization has added GLP-1 drugs to treat diabetes to its essential medicines list, alongside treatments ...

Medical experts discuss whether GLP-1 medications, including Mounjaro and Zepbound, could become comprehensive treatments for ...

The World Health Organization (WHO) has officially included GLP-1 receptor agonists, such as Novo Nordisk’s Ozempic and Eli ...

Eli Lilly is on track to release orforglipron next year, which has showed an average of 12 percent weight loss.

A class action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lily’s ...

GLP-1 weight loss drugs like Ozempic and Mounjaro are booming, but their impact on gut health is raising critical questions.

The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like ...

Lots of research suggests such medications must be used indefinitely to maintain weight loss and related health benefits. But ...

A journey in weight loss can be a long and challenging one for many people. New data from Hims & Hers looking at thousands of ...

An increasing proportion of bariatric surgery patients are taking GLP-1 weight-loss drugs in the years following their ...

GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...